# A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

> **NCT01682863** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 614 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** QVA149
- **DRUG:** QVA149
- **DRUG:** QAB149
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01682863
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682863, "A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01682863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*